This week, Pfizer (#163 of the Global 5000 list) announced it was acquiring King Pharmaceuticals (#2441 on our list). This will add another $1.7 billion of revenue to Pfizer and move them up a few notches on our list.
As always, those who sell products and services to King will now have to monitor the situation closely to see (once the deal is done) if the company operations get merged or still operate independently. It will affect how the account is covered and how they buy. These type of events don’t happen overnight and usually have a long approval process so keeping track is important for sales forecasts and territory planning.